[Early virologic response in retherapy with pegylated interferon alpha-2B plus ribavirin in children with chronic hepatitis C].
The aim of the study was evaluation of EVR in children with chronic hepatitis C retreated with PegIFN and ribavirin. We enrolled 13 children (11 boys and 2 girls) with CHC, median age 13,9 years, previously treated with IFN monotherapy (n-4) or combined IFN+ RBV (n-9) during 12 months, mean interval for previous therapy 2,7 years, infected with HCV genotypes 1 (n-6) and type 4 (n-7), mean baseline ALT activity 65,3 U/l, HCV-RNA 488.315 IU/ml. HCV RNA was evaluated with PCR method (Amplicor Roche test), HCV genotypes with InnoLipa test. All children received pegylated IFN-alpha 2b 1,5 mcg/kg/week and ribavirin 15 mg/kg/day. EVR was defined as decrease of HCV RNA > 2 log10 to baseline or serum undetectable in 12 week of treatment. EVR was observed in 6/12 (50%) of children. EVR was more common in children < 13 years old and with shorter interval for end of previous therapy, higher baseline ALT activity (p<0,05) and lower HCV viral load. In patients with EVR more common leucopenia <3.000/ml was observed. 1 patient discontinued therapy because of depression. 1. Pegylated IFN alpha-2b with RBV seems to be effective in children with chronic hepatitis C previously non responded to therapy. 2. Factors associated with favorable treatment prognosis include high baseline ALT activity, lower viral load, shorter interval for end of previous treatment and younger age.